Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ORLANDO PUENTE

NPI
1811976459
CMS profile
1289288
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$152.98

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $152.98 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Bard Peripheral Vascular, Inc. $152.98 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ORLANDO PUENTE

NPI 1811976459 · CMS profile ID 1289288

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811976459?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ORLANDO PUENTE, NPI 1811976459, CMS profile ID 1289288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811976459?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ORLANDO PUENTE, NPI 1811976459, CMS profile ID 1289288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811976459?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ORLANDO PUENTE, NPI 1811976459, CMS profile ID 1289288, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1811976459?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $152.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bard Peripheral Vascular, Inc. $106.3303/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748100137 CMS
Bard Peripheral Vascular, Inc. $46.6501/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748100171 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $369.99 5
PY2020 $152.98 2
PY2021 $110.70 1
PY2022 $360.71 7
PY2023 $102.32 1
PY2025 $123.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $2,235,212.65 131
PY2024 Recipient $6,424.00 1
PY2024 Principal investigator $2,519,821.99 65
PY2023 Recipient $300.00 1
PY2023 Principal investigator $2,960,886.91 78
PY2022 Recipient $803.00 1
PY2022 Principal investigator $3,163,802.40 54
PY2021 Recipient $244,761.00 2
PY2021 Principal investigator $701,141.03 18
PY2020 Principal investigator $312,360.32 152
PY2019 Principal investigator $247,110.23 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

152 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,065.30 12/15/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737094267
Principal investigator 1 Eisai Inc. $1,615.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102035
Principal investigator 1 Eisai Inc. $3,432.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102037
Principal investigator 1 Eisai Inc. $2,048.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102039
Principal investigator 1 Eisai Inc. $1,000.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102041
Principal investigator 1 Eisai Inc. $1,500.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102043
Principal investigator 1 Eisai Inc. $1,000.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102065
Principal investigator 1 Eisai Inc. $1,500.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102067
Principal investigator 1 Eisai Inc. $1,000.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102069
Principal investigator 1 Eisai Inc. $2,724.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102071
Principal investigator 1 Eisai Inc. $1,545.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102073
Principal investigator 1 Eisai Inc. $1,842.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102077
Principal investigator 1 Eisai Inc. $1,361.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102079
Principal investigator 1 Eisai Inc. $2,255.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102081
Principal investigator 1 Eisai Inc. $3,248.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102083
Principal investigator 1 Eisai Inc. $1,615.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102105
Principal investigator 1 Eisai Inc. $3,444.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102107
Principal investigator 1 Eisai Inc. $3,432.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102109
Principal investigator 1 Eisai Inc. $2,048.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102111
Principal investigator 1 Eisai Inc. $2,476.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102113
Principal investigator 1 Eisai Inc. $1,000.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102115
Principal investigator 1 Eisai Inc. $1,000.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102117
Principal investigator 1 Eisai Inc. $1,000.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102119
Principal investigator 1 Eisai Inc. $1,000.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102121
Principal investigator 1 Eisai Inc. $1,500.00 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102123
Principal investigator 1 Eisai Inc. $29,544.45 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102311
Principal investigator 1 Eisai Inc. $743.75 07/21/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102333
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102025
Principal investigator 1 Eisai Inc. $1,000.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102027
Principal investigator 1 Eisai Inc. $3,248.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102029
Principal investigator 1 Eisai Inc. $1,615.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102031
Principal investigator 1 Eisai Inc. $3,248.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102033
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102075
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102145
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102147
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102149
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102151
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102153
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102155
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102157
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102159
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102161
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102163
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102177
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102179
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102181
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102183
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102185
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102187
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102189
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102191
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102193
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102195
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102197
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102199
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102201
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102203
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102205
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102207
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102209
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102211
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102213
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102215
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102217
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102219
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102221
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102231
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102233
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102235
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102237
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102239
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102241
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102243
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102245
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102247
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102249
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102251
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102253
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102255
Principal investigator 1 Eisai Inc. $669.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102257
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102259
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102261
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102263
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102265
Principal investigator 1 Eisai Inc. $950.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102267
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102269
Principal investigator 1 Eisai Inc. $1,655.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102271
Principal investigator 1 Eisai Inc. $550.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102273
Principal investigator 1 Eisai Inc. $3,248.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102275
Principal investigator 1 Eisai Inc. $1,615.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102277
Principal investigator 1 Eisai Inc. $3,444.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102279
Principal investigator 1 Eisai Inc. $1,615.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102281
Principal investigator 1 Eisai Inc. $3,229.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102283
Principal investigator 1 Eisai Inc. $1,615.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102285
Principal investigator 1 Eisai Inc. $3,432.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102287
Principal investigator 1 Eisai Inc. $3,248.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102289
Principal investigator 1 Eisai Inc. $1,615.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102291
Principal investigator 1 Eisai Inc. $3,444.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102293
Principal investigator 1 Eisai Inc. $1,615.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102295
Principal investigator 1 Eisai Inc. $1,662.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102297
Principal investigator 1 Eisai Inc. $3,229.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102299
Principal investigator 1 Eisai Inc. $1,615.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102301
Principal investigator 1 Eisai Inc. $3,432.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102303
Principal investigator 1 Eisai Inc. $1,500.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102305
Principal investigator 1 Eisai Inc. $2,048.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102307
Principal investigator 1 Eisai Inc. $2,476.00 07/16/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 06/30/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737084207
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102013
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102015
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102017
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102019
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102021
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102023
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102045
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102047
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102049
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102051
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102053
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102055
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102057
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102059
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102061
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102063
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102085
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102087
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102089
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102091
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102093
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102095
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102097
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102099
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102101
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102103
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102125
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102127
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102129
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102131
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102133
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102135
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102137
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102139
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102141
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102143
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102165
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102167
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102169
Principal investigator 1 Eisai Inc. $1,705.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102171
Principal investigator 1 Eisai Inc. $1,075.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102173
Principal investigator 1 Eisai Inc. $1,075.00 03/31/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102175
Principal investigator 1 Eisai Inc. $2,651.00 02/07/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749101957
Principal investigator 1 Eisai Inc. $2,651.00 02/07/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749101959
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,141.82 01/01/2020 Non-covered Recipient Entity
MIAMI DADE MEDICAL RESEARCH INSTITUTE INC
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD No dispute reported 06/30/2026 721493489